1 Eyepath Lab, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, Københavns Universitet2 unknown3 BRAIN Lab, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, Københavns Universitet4 BRAIN Lab, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, Københavns Universitet
study protocol for a randomised controlled trial
One of the main causes of mortality and morbidity following subarachnoid haemorrhage (SAH) is the development of cerebral vasospasm, a frequent complication arising in the weeks after the initial bleeding. Despite extensive research, to date no effective treatment of vasospasm exists. Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation. In vitro models have shown a relaxing effect of prostacyclin after induced contraction in cerebral arteries, and a recent pilot trial showed a positive effect on cerebral vasospasm in a clinical setting. No randomised, clinical trials have been conducted, investigating the possible pharmacodynamic effects of prostacyclin on the human brain following SAH.
Trials, 2012, Vol 13, p. 1-6
Cerebral Angiography; Cerebral Arteries; Cerebrovascular Circulation; Denmark; Epoprostenol; Glasgow Coma Scale; Humans; Infusions, Parenteral; Microdialysis; Perfusion Imaging; Pilot Projects; Regional Blood Flow; Research Design; Subarachnoid Hemorrhage; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vasoconstriction; Vasodilator Agents; Vasospasm, Intracranial